There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ziopharm Oncology (NASDAQ: ZIOP) and Beyondspring Inc (NASDAQ: BYSI) with bullish sentiments.
Ziopharm Oncology (NASDAQ: ZIOP)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ziopharm Oncology (NASDAQ: ZIOP), with a price target of $5.50. The company’s shares closed yesterday at $3.51, close to its 52-week low of $3.33.
Ramakanth noted:
“We note that the PoC CAR-T program has yet to enter the clinic and that rather than safety concerns, the FDA requested additional CMC information, which is not unexpected for an entirely new CAR-T manufacturing process. Furthermore, we note that neither of the Ziopharm’s clinical programs on Ad-RTS-hIL-12 or second generation CAR-Ts has been affected. In our view, the clinical hold is more akin to the FDA putting a “pause” on the IND review process while the company prepares the response. Ziopharm plans to meet with their partners on the CAR-T program, Intrexon (XON; not rated) and MD the coming week discuss the response to the FDA.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 9.4% and a 40.3% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.
Ziopharm Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
See today’s analyst top recommended stocks >>
Beyondspring Inc (NASDAQ: BYSI)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Beyondspring Inc (NASDAQ: BYSI), with a price target of $60. The company’s shares closed yesterday at $26.88.
Pantginis noted:
“We recently held a KOL call with Dr. Douglas Blayney, an oncologist and Medical Center. He was also a former president of the Clinical Oncology. He has served on FDA and serves as an investigator for trials of both Neulasta and Plinabulin. Further, he was previously a founding member for the NCCN guidelines for the treatment of neutropenia. Before discussing the clinical profile and opportunity of Plinabulin, Dr. Blayney highlighted some drug’s background. Plinabulin is a marine-derived small molecule in late-stage clinical development for CIN and NSCLC. Plinabulin is currently in two Phase 2/3 studies, 106 targeting docetaxel intermediate risk CIN, and TAC high risk chemo patients, respectively.”
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -8.7% and a 36.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Beyondspring Inc is Moderate Buy and the average price target is $56, representing a 108.3% upside.
In a report issued on June 4, Maxim Group also maintained a Buy rating on the stock with a $52 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
